#baf312

Novartis, nueva droga para combatir esclerosis múltiple

La droga en investigación de Novartis para la esclerosis múltiple (enfermedad autoinmune que afecta el sistema nervioso central) redujo el riesgo de progresión de la discapacidad en los pacientes de manera firme en el tratamiento de la enfermedad en comparación con un placebo, señaló la empresa suiza, citando un nuevo análisis de un ensayo en etapa tardía.

Novartis está probando BAF312 contra la…

Positive Results Announced from Clinical Trial of BAF-312 (Siponimod) in Secondary Progressive MS

Summary

Results presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) provided additional details from a 60-month, phase III clinical trial of the experimental oral therapy siponimod (BAF312, Novartis Pharmaceuticals AG) involving 1,651 people with secondary progressive MS.

The trial met its primary endpoint of reducing the risk of…

Novartis annuncia gli incoraggianti risultati della fase III dello studio EXPAND (siponimod)

A Basilea il 25 agosto scorso, la casa farmaceutica Novartis ha annunciato la fase III dello studio EXPAND, per valutare l’efficacia e la sicurezza del farmaco per bocca (via orale), una volta al giorno, BAF312 (siponimod) per la sclerosi multipla secondaria progressiva (SMSP). Tale farmaco ha raggiunto l’endpoint primario essendo stato in grado di ridurre il rischio di progressione della…

Novartis announces positive phase III results showing effectiveness of BAF312 in patients with secondary progressive multiple sclerosis

August 25, 2016

Novartis has announced the results of the Phase III EXPAND study that evaluates the safety and efficacy of oral, once-daily, BAF312 (siponimod) in secondary progressive multiple sclerosis (SPMS). The study confirmed that BAF312 met its primary endpoint of a reduction in the risk of disability progression, compared with placebo. This EXPAND study represents the largest randomized,…

Positive phase III results showing efficacy of #BAF312 in patients with secondary progressive MS @WHO

News Hour:

The EXPAND study is a randomized, double-blinded, placebo-controlled Phase III study, comparing the efficacy and safety of BAF312 versus placebo in people with secondary progressive multiple sclerosis (SPMS). The EXPAND study is the largest randomized, controlled study in SPMS to date.

Novartis announced the Phase III EXPAND study, evaluating the efficacy and safety of oral,…